Currently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast; subjects are considered to have a currently active malignancy if they have completed anti-cancer therapy and have not been disease free for > 2 years
Subjects with a \currently active\ second malignancy other than non-melanoma skin or superficial urothelial cancers are not eligible; subjects are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered without evidence of disease for 2 years prior to cycle 1 day 1
Patients with a “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 years
Subjects with a “currently active” second malignancy other than non-melanoma skin cancers or non-invasive bladder cancers or other in-situ or non-invasive malignancies. Subjects are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 years
No other active second malignancy other than non-melanoma skin cancers and in situ cervical cancers within 5 years of registration\r\n* NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 5 years prior to registration
Currently active second malignancy other than non-melanoma skin cancer or carcinoma in-situ of the cervix; patients are not considered to have a “currently active” malignancy if they have completed therapy and have no evidence of recurrence for at least 5 years
Patients with a second active malignancy, exceptions are localized non-melanoma skin cancers or prior in situ carcinoma
Patients with a “currently active” second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, “low risk” adenocarcinoma of the prostate and carcinoma in situ of the cervix; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 2 years
Subjects with a “currently active” second malignancy, other than non-melanoma skin cancers are not eligible
Patients with a current second malignancy requiring systemic therapy, other than non-melanoma skin cancers, are not eligible; if a patient has had a prior second malignancy that is not currently requiring active treatment, the patient will be considered eligible
Currently active second malignancy other than non-melanoma skin cancers
Currently active second malignancy other than non-melanoma skin cancers
No other active second malignancy other than non-melanoma skin cancers within 3 years of pre-registration; a second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 3 years prior to pre-registration
Patients with known active second malignancy other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast. Patients are not considered to have a currently active malignancy if they have completed anticancer therapy and have been disease free for greater than 2 years prior to screening;
Second malignancy other than non-melanoma skin cancers within the past 5 years
Second malignancy: No \currently active\ second malignancy other than non-melanoma skin cancers.
Currently active second primary malignancy or history of malignancy less than 5 years prior to the time of study eligibility (patients with history of skin cancers excluding melanoma will be eligible for participation)
Patients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year
Patients with a “currently active” second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, “low risk” adenocarcinoma of the prostate and carcinoma in situ of the cervix; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 2 years
Currently active second primary malignancy, including hematologic malignancies, except for non-melanoma skin cancers, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast; subjects are considered to have a currently active malignancy if they have completed anti-cancer therapy and have not been disease free for > 2 years
Subjects with a “currently active” second malignancy, other than non-melanoma skin cancers are not eligible
Currently active second malignancy, except non-melanoma skin cancer
Currently active second malignancy other than non-melanoma skin cancer or carcinoma in-situ of the cervix. Patients are not considered to have a \currently active\ malignancy if they have completed therapy and have no evidence of recurrence for at least 5 years.
Patients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year
Patients with a “currently active” second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, “low risk” adenocarcinoma of the prostate and carcinoma in situ of the cervix; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 years
Patients with a, “currently active,” second malignancy other than non-melanoma skin cancers or non-invasive bladder cancers or other in-situ or non-invasive malignancies; patients who have completed therapy for a prior malignancy and are free of disease for >= 3 years are eligible
Patients with a \currently active\ second malignancy other than non-melanoma skin or superficial urothelial cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered without evidence of disease for 2 years
Patients with a “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 years
Patients with an active second malignancy (other than non-melanoma skin cancer or cervical carcinoma in situ) are NOT eligible for participation; patients who have a history of malignancy are not considered to have a currently active malignancy if they have completed therapy and are now considered by their physician to be at < 30% risk for relapse
Patients with a currently active second malignancy other than non-melanoma skin cancer. Patients are not considered to have a currently active malignancy if they have completed necessary therapy and are considered by their physician to be at <30% risk of relapse at time of assessment.
Currently, no active second malignancy other than non-melanoma skin cancer; note: patients are not considered to have a \current active\ malignancy if they have completed anti-cancer therapy and are considered by their physicians to have a less than 30% chance of relapse
Participants with an active second malignancy (other than non-melanoma skin cancer or cervical carcinoma in situ). Participants who have a history of malignancy are not considered to have an active malignancy if they have completed therapy and are considered by their treating physician to be at <= 30 percent (%) risk for relapse
Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention, other than non-melanoma skin cancer and carcinoma in situ of the cervix should not be enrolled; patients are not considered to have a “currently active” malignancy if they have completed therapy for a prior malignancy, are disease free from a prior malignancy for >= 5 yrs and are considered by their physician to be less than 30% risk of relapse
Patients with a currently active second malignancy excluding non-melanomatous skin cancer or superficial transitional cell carcinoma\r\n* Note: Patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year
Patients with another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer; patients that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollment
\Currently active\ second malignancy other than non-melanoma skin cancers or non-muscle invasive transitional cell carcinoma of bladder; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered (by their physician) to be at less than 30% risk for relapse
Having \currently active\ second malignancy unrelated to HL or NHL, unless they have completed anti-cancer therapy, are in complete response and are considered by their physicians to be at less than 30% risk of relapse
Active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ; (patients with history of malignancy are not considered to have a “currently active” malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)
Active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ; (patients with history of malignancy are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)
Patients may not have a \currently active\ second malignancy other than non-melanoma skin cancers; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
Concurrent active malignancy other than non-melanoma skin cancers; patients are considered to be free of active malignancy if they have completed curative therapy and have a < 30% risk of relapse
Patients must not have another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer; patients that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollment
Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention, other than non-melanoma skin cancer and carcinoma in situ of the cervix should not be enrolled; patients are not considered to have a “currently active” malignancy if they have completed therapy for a prior malignancy, are disease free from a prior malignancy for >= 5 yrs and are considered by their physician to be less than 30% risk of relapse
Patients with a \currently active\ second malignancy other than non-melanoma skin cancers are not to be registered; patients are not considered to have a \currently active\ malignancy if they have completed therapy and considered by their physician to be at less than 30% risk of relapse
Patients may not have a \currently active\ second malignancy other that non-melanoma skin cancers; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
Patients with a “currently active” second malignancy, other than non-melanoma skin cancer or in situ carcinoma of the cervix or breast; patients are not considered to have a “currently active” malignancy if they have completed anti-cancer therapy, are considered by their physician to be at less than 30% risk of relapse and at least 2-5 years have lapsed
No currently active other (second) malignancy, other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed anti-cancer therapy and are considered by their physicians to be at less than 30% risk of relapse
“Currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy more than 3 years ago and are considered to have a less than 30% risk of relapse based on the enrolling investigator’s assessment and documented in the medical record; a history of prostate cancer that was identified incidentally following cystoprostatectomy or cystectomy for bladder cancer is acceptable, provided that the following criteria are met: \r\n* Stage T2N0M0 or lower \r\n* Gleason score =< 7, negative margins at surgery, and prostate specific antigen (PSA) undetectable after surgery
No “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
Having \currently active\ second malignancy unrelated to Hodgkin lymphoma (HL) or NHL, unless they have completed anti-cancer therapy, are in complete response and are considered by their physicians to be at less than 30% risk of relapse
Any \currently active\ second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a \currently active\ malignancy, if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse over next 3 months.
Patients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed anti-cancer therapy and are considered by their physician to be at less than 30% risk of relapse
Patients with a \currently active\ second malignancy other than non-melanoma skin cancer are excluded; (patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse)
\Currently active\ second malignancy (other than non-melanoma skin cancer, carcinoma in situ of the cervix or prostatic intraepithelial neoplasia within 1 year). Subjects are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within 1 year.
Any “currently active” second malignancy, other than non-melanoma skin cancer; patients are not considered to have a \currently active” malignancy, if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse over next year
Currently active other malignancy excluding controlled non-melanoma skin cancer. Patients are considered NOT to have \currently active\ malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.
